FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number 3235-0104 Estimated average burden

|   |                  |   | pursuant to S | Section 16(a) of the Securities Exchange Act of 1934 |  |   |  |   | hours per res                         | ponse:                                      | 0.5  |  |    |
|---|------------------|---|---------------|--|--|---|--|---|---------------------------------------|---|--|--|----|
| 1. Name and Address of Reporting Person*         2. Date of Event Requiring Statement<br>(Month/Day/Year)           07/09/2010         07/09/2010 |                  |   |               |  |  | 30(h) of the Investment Company Act of 1940<br>3. Issuer Name and Ticker or Trading Symbol<br><u>VERTEX PHARMACEUTICALS INC / MA</u> [ VRTX ] |  |   |                                       |   |  |  |    |
| (Last) (First) (Middle)<br>C/O VERTEX PHARMACEUTICALS INCORPORATED<br>130 WAVERLY STREET<br>(Street)<br>CAMBRIDGE MA 02139                        |                  | _ |               |  | 4. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director<br>Officer (give title below) |   | 10% Owner<br>Other (specify below)                         |   |                                       | vidual or Joint/Group F<br>Form filed by On | ndment, Date of Original Filed (Month/Day/Year)<br>ual or Joint/Group Filing (Check Applicable Line)<br>Form filed by One Reporting Person<br>Form filed by More than One Reporting Person |  |    |
| (City)  | /) (State) (Zip) |   |               |  |  |   |  |   |                                       |   |  |  |    |
|   |                  |   |               | Table  | I - Non-De   | erivative S   | Securities Beneficially Owned                              | l   |                                       |   |  |  |    |
| 1. Title of Security (Instr. 4)   |                  |   |               |  |  | 2. Amount o<br>(Instr. 4)   | f Securities Beneficially Owned                            | 3. Ownership Form: Direct<br>(D) or Indirect (I) (Instr. 5) |                                       | 4. Nature                                   | e of Indirect Benefici   | al Ownership (Instr. 5)                                  |    |
| Common Stock  |                  |   |               |  |  |   | <b>0</b> <sup>(1)</sup>                                    | D   |                                       |   |  |  |    |
|   |                  |   |               |  |  |   | curities Beneficially Owned options, convertible securitie | es)   |                                       |   |  |  |    |
| 1. Title of Derivative Security (Instr. 4)<br>2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)                                      |                  |   |               |  | ate  | (Instr. 4) Exercis<br>of Deriv  |  |   | 4. Conver<br>Exercise I<br>of Derivat | Price                                       | 5. Ownership<br>Form: Direct (D) or<br>Indirect (I) (Instr. 5)   | 6. Nature of Indirect Beneficial<br>Ownership (Instr. 5) | al |
|   |                  |   |               | Date<br>Exercisable                                  | Expiration<br>Date   | Title   |  | Amount or<br>Number of<br>Shares                            | - Security                            |   |  |  |    |
| Explanation of Respon I. No securities benefically  |                  |   |               |  |  |   |  |   |                                       |   |  | <u>a</u>   |    |

Remarks:

Kenneth S. Boger, Attorney-In-Fact \*\* Signature of Reporting Person

07/13/2010 Date

\*
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 76ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned hereby constitutes and appoints each of Kenneth S. Boger, Valerie L. Andrews and Omar White of Vertex Pharmaceuticals Incorporated (the "Company"),

execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, forms and authenticatio
 do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authenticatior
 execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in acc
 do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and time!
 take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best ir
 The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, neces

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersig

This Power of Attorney is intended to constitute a "confirming statement" for presentation to the Securities and Exchange Commission as contemplated by Instru

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 9th day of July, 2010.

/s/ Wayne J. Riley Signature

Wayne J. Riley Print Name

74252.1